About Aegera Therapeutics
Aegera Therapeutics is a Healthcare company based in Montreal (Canada) founded in 2000, and was acquired by PharmaScience in May 2011. Small molecule therapeutics for cancer and immune diseases are developed. Aegera Therapeutics has raised $37.9 million across 5 funding rounds from investors including Desjardins, PharmaScience and BDC. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Aegera Therapeutics, part of Pharmascience, is focused on developing targeted therapeutics to address major unmet medical needs. Aegera focuses on preclinical and early-stage clinical development through integration of in-house medicinal chemistry, biochemistry, cell biology, pharmacokinetics and in vivo pharmacologyefficacy. Aegera has one oncology program in clinical development and several preclinical programs. HGS1029 is a small molecule pan-IAP inhibitor that has demonstrated very promising preclinical activity across a broad range of cancers. A license and collaboration agreement was completed in December 2007 with Human Genome Sciences and HGS1029 is currently progressing in Phase 1 - solid tumor study. Aegera has several preclinical stage programs targeting key proteins involved in oncology and autoimmuneinflammatory diseases, including a small molecule Brutons tyrosine kinase (Btk) inhibitor program.
- Headquarters Montreal, Canada
- Stage Acquired
- SectorsHealthcare
- Website aegera.com
- Social LinkedIn Facebook
- Acquired by PharmaScience (May 2011)
- Total Equity Funding$37.9M (USD)
in 5 rounds
- Latest Funding Round$6.53M (USD), Debt – Conventional
Sep 2009
- InvestorsDesjardins
& 11 more
- Acquired byPharmaScience
(May 2011)
Funding Insights of Aegera Therapeutics
Aegera Therapeutics has successfully raised a total of $37.9M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $6.53 million completed in September 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.9M
- Total Rounds 5
- Last Round Debt – Conventional — $6.53M
- First Round $10.7M
(Feb 2002)
- Investors Count 11
All 5 funding rounds of Aegera Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2009 | $6.53M | Debt – Conventional | – | – | |
| Nov 2006 | $6.1M | Debt – Conventional | – | – | – |
| Oct 2006 | $12.2M | Series C | – | – | |
| Feb 2004 | $15M | Series C | – | – | |
| Feb 2002 | $10.7M | Series B | – | – |
12 investors in total: 12 institutional.
Investors in Aegera Therapeutics
Aegera Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Desjardins, PharmaScience and BDC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity buyouts are targeted by the investment firm. | vgpartners.com | Toronto, Canada | ||
Stage-agnostic sector-agnostic VC firm investing in Canada and the US | growthworks.ca | Vancouver, Canada | ||
| genechem.com | ||||
| t2c2capital.com | ||||
| medtechpartners.com | ||||
Business guidance for corporate companies and startups | investquebec.com | Quebec City, Canada | ||
Commercial banking services for small and medium-sized enterprises are provided. | 1944 | bdc.ca | Montreal, Canada | |
Financial services are provided cooperatively to members in Canada. | 1900 | desjardins.com | Levis, Canada | |
Offers savings plans, investments, and financing for businesses and individuals. | 1983 | fondsftq.com | Montreal, Canada | |
Offers sustainable finance and REER for individuals and businesses. | 1996 | fondaction.com | Montreal, Canada |
Investor details for Aegera Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Aegera Therapeutics
4 dated milestones of Aegera Therapeutics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Aegera Therapeutics is founded.
- Funding First funding round of $10.7M.
- Funding Latest funding round, Debt – Conventional, of $6.5M.
- Exit Acquired by PharmaScience.
Web traffic of Aegera Therapeutics
Websites that share an audience with Aegera Therapeutics (aegera.com).
Websites whose visitors overlap most with Aegera Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| epocal.com | 100% | View details | |||
oxoid.ca | oxoid.ca | 100% | – | ||
| informationmediary.com | 100% | 2.6K | #6,664,316 | View details | |
| pharmagap.com | 100% | View details | |||
| coleypharma.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Aegera Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aegera Therapeutics
Complete news archive for Aegera Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aegera Therapeutics
Aegera Therapeutics was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Aegera Therapeutics is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Aegera Therapeutics is a funded company, having raised a total of $37.9M across 5 funding rounds to date. The company's 1st funding round was a Series B of $10.7M, raised on Feb 2002.
Aegera Therapeutics, part of Pharmascience, is focused on developing targeted therapeutics to address major unmet medical needs. Aegera focuses on preclinical and early-stage clinical development through integration of in-house medicinal chemistry, biochemistry, cell biology, pharmacokinetics and in vivo pharmacologyefficacy. Aegera has one oncology program in clinical development and several preclinical programs. HGS1029 is a small molecule pan-IAP inhibitor that has demonstrated very promising preclinical activity across a broad range of cancers. A license and collaboration agreement was completed in December 2007 with Human Genome Sciences and HGS1029 is currently progressing in Phase 1 - solid tumor study. Aegera has several preclinical stage programs targeting key proteins involved in oncology and autoimmuneinflammatory diseases, including a small molecule Brutons tyrosine kinase (Btk) inhibitor program.
Aegera Therapeutics has 12 investors. Key investors include Desjardins, PharmaScience, BDC, Invest Quebec, and VenGrowth VG Partners.
Yes. Aegera Therapeutics was acquired by PharmaScience in May 2011.